Related by context. All words. (Click for frequent words.) 72 drug conjugate ADC 71 IMC #B 70 IgG1 monoclonal antibody 70 IMA# 70 targeting CD# 70 investigational humanized monoclonal antibody 70 IAP inhibitor 70 humanized monoclonal antibodies 70 M2 subunit 69 mertansine 69 Elotuzumab 69 PSMA ADC 69 MT#/MEDI-# 69 HER2 antibody 69 chimeric monoclonal antibody 69 oncolytic 69 proteasome inhibitor 69 targeted antifolate 68 IgG1 antibody 68 humanized monoclonal antibody 68 TRX1 68 humanized anti 68 selective kinase inhibitor 68 MMAE 68 liposomal formulation 68 Daclizumab 68 accumulate preferentially 68 AEG# 68 HuLuc# 68 CD4 monoclonal antibody 68 VitiGam 68 CYT# potent vascular disrupting 68 Phase #b/#a clinical 68 IAP inhibitors 68 cilengitide 68 Nanobody 68 Locked Nucleic Acid 68 HGS ETR2 68 potent cytotoxic 68 CD# monoclonal antibody 68 antibody MAb 68 volociximab 68 humanized monoclonal 67 MT# MEDI 67 Potelligent Technology 67 MAGE A3 ASCI 67 immunotoxin 67 anti CD3 monoclonal 67 alpha folate receptor 67 CD# CEA 67 GVAX ® 67 Fc fusion protein 67 Trastuzumab DM1 67 MEK inhibitor 67 Panzem R NCD 67 BiTE R 67 telomerase therapeutic 67 oncolytic virus therapies 67 Aflibercept 67 TLR9 agonist 67 monoclonal antibody mAb 67 anti CD# monoclonal 67 Pertuzumab 67 investigational monoclonal antibody 67 GRNVAC1 67 JAK1 67 apoptosis proteins 67 recombinant adeno associated 67 virus AAV 67 PEG SN# 67 isoform selective 67 humanized antibody 67 oral proteasome inhibitor 67 agonistic human 66 Factor VIIa 66 CBLC# 66 attach auristatin 66 multi kinase inhibitor 66 Cyclosert TM 66 huC# DM4 66 investigational immunotherapy 66 pan HDAC inhibitor 66 Panzem NCD 66 NPC 1C 66 AQ4N 66 Sym# 66 Allovectin 7 66 bispecific antibody 66 Proxinium TM 66 adecatumumab MT# 66 lintuzumab SGN 66 NTDDS 66 immunoconjugate 66 FOLOTYN ® 66 Antibody Drug Conjugate 66 PKC# 66 personalized immunotherapy 66 mRNA antagonists 66 Micromet BiTE 66 PNP inhibitor 66 humanised monoclonal antibody 66 epothilones 66 oral prodrug 66 GRN#L 66 PDX pralatrexate 66 ASG 5ME 66 cathepsin K inhibitor 66 Cyclosert 66 antibody MT# 66 PORxin TM 66 CD# antibody [001] 66 XL# XL# 66 histone deacetylase HDAC 66 HSP# inhibitor 66 reslizumab 66 anti CD# antibody 66 vascular disrupting agents 66 Litx 66 Aurora kinase inhibitor 66 chemically modified siRNA 66 targeted radiotherapeutic 65 oral kinase inhibitor 65 Micromet proprietary BiTE 65 pertuzumab 65 CD# expressing 65 ribonucleotide reductase clinically validated 65 human monoclonal antibody 65 metaglidasen 65 AAG geldanamycin analog 65 PI3K/Akt pathway inhibitor 65 dasatinib Sprycel 65 proprietary BiTE ® 65 tyrosine kinase inhibitor 65 novel immunotherapeutic 65 novel topoisomerase 65 immunotherapeutic agent 65 vaccine GRNVAC1 65 Tarvacin TM 65 oncolytic virus 65 CD3 monoclonal antibody 65 anticancer therapeutics 65 Kinase Inhibitor 65 proprietary polysaccharide 65 Pradefovir 65 hypoxia activated prodrug 65 cancer immunotherapies 65 CEQ# 65 alvespimycin 65 Tarvacin 65 Phase Ib clinical trials 65 POTELLIGENT R 65 non nucleoside inhibitor 65 Angiocept 65 murine monoclonal antibody 65 depsipeptide 65 Aganocide ® 65 Protein Kinase C 65 PLK1 SNALP 65 bevacizumab Avastin ® 65 epothilone 65 Cloretazine 65 BiTE 65 evaluating satraplatin 65 Tumour Vascular Disrupting Agent 65 EndoTAG 65 Aplidin R 65 selective androgen receptor modulator 65 Payload TAP technology 65 Annamycin 65 POTELLIGENT ® 65 Curaxin CBLC# 65 docetaxel Taxotere R 65 CYC# 65 IMC A# 65 Insegia 65 AKT inhibitor 65 polymerase inhibitor 65 MCSP respectively 65 Virulizin ® 65 5 fluorouracil leucovorin 65 LymphoStat B belimumab 65 antisense inhibitors 65 bispecific 65 trastuzumab DM1 65 orally administered inhibitor 65 CDK cyclin dependent 65 JAK2 inhibitor 65 Romidepsin 65 recombinant subunit vaccine 65 platinum chemotherapeutic 65 trastuzumab Herceptin R 65 KSP inhibitor 65 XmAb# 65 MyVax R 65 therapeutic monoclonal antibody 65 Lenocta 65 Fleximer 65 liposomal delivery 65 selective orally bioavailable 65 delta isoform 65 SAR# [004] 65 alkylating agent 65 DCVax R 65 MKC# MT 65 OncoVEX GM CSF 65 ENMD # 65 protein tyrosine phosphatase 1B 64 HGS ETR1 64 PEGylated interferon 64 ADP receptor antagonist 64 Alfacell proprietary ribonuclease 64 ARRY # 64 hormone LHRH antagonist 64 Solazed ™ 64 novel immunotherapies 64 Archexin 64 HER1 64 TG# [001] 64 ganetespib 64 Temsirolimus 64 entinostat 64 Otelixizumab 64 antisense oligonucleotides 64 DNA intercalator 64 novel peptide 64 poly ADP ribose polymerase 64 Exherin TM 64 peptidomimetic 64 PI3K/mTOR 64 telomerase inhibitor drug 64 Blinatumomab 64 XmAb 64 c Raf kinase 64 Avila Therapeutics 64 Initiates Phase II 64 luteinizing hormone releasing 64 Onconase 64 PARP inhibitor 64 OMP #M# 64 HyperAcute 64 human IgG1 monoclonal 64 Omacetaxine 64 HCV polymerase 64 HGS ETR1 mapatumumab 64 immatics 64 siRNA therapeutic 64 erlotinib Tarceva 64 Immunotherapeutic 64 PRT# 64 JAK inhibitor 64 Liposomal 64 Tesetaxel 64 Rigel R# 64 Selective Electrochemical Tumor Ablation 64 nucleoside analog 64 small molecule tyrosine 64 PrevOnco 64 Nexavar ® 64 peptibody 64 taxane derivative 64 Oncolytic 64 MorphoSys proprietary 64 orally bioavailable 64 monoclonal antibody MAb 64 Monoclonal antibody 64 HuMax 64 DOS# 64 Kosan dependence 64 Cloretazine ® 64 triggers apoptosis programmed 64 Pralatrexate 64 CCX# 64 ImmunoGen TAP technology 64 HCV protease inhibitor 64 LHRH antagonist 64 antibody trastuzumab 64 diarrhea predominant irritable 64 Aptamer 64 small molecule glucokinase 64 selective immunoproteasome inhibitor 64 ALN PCS 64 Phase Ib II 64 essential thrombocythemia ET 64 MTP inhibitor 64 HuMax HepC TM 64 R roscovitine 64 histone deacetylase HDAC inhibitor 64 HCD# [002] 64 CCR9 antagonist 64 lumiliximab 64 A3 adenosine receptor 64 HepDirect 64 specific lectin receptors 64 Aplidin 64 elotuzumab 64 investigational antibody 64 HuMax EGFr 64 ATL# [001] 64 anti CD3 64 subcutaneous formulation 64 protein kinase inhibitor 64 cetuximab Erbitux R 64 candidate AQ4N 64 irreversible inhibitor 64 TKB# 64 eniluracil 64 vinca alkaloid 64 MVA BN R 64 Camptosar ® irinotecan 64 Factor Receptor 64 IMiDs R 64 Janus Kinase 64 proprietary BiTE R 64 lentiviral vector 64 recombinant fusion 64 PDE4 inhibitor 64 systemic RNAi therapeutic 64 GW# [003] 64 OncoVEX 63 Personalized Immunotherapy 63 HER pathway 63 oral Janus kinase 63 XYOTAX TM 63 LHRH receptor positive 63 Quinamed 63 dasatinib Sprycel ® 63 Scancell 63 nucleoside reverse transcriptase inhibitor 63 evaluating tivozanib 63 Locked Nucleic Acid LNA 63 kidney urologic 63 HuMax TAC 63 Intravenous CP 63 JAK2 Inhibitor 63 Ophthotech 63 Presents Preclinical Data 63 LymphoStat B TM 63 Zalypsis 63 Vitaxin 63 delipidation 63 MGd 63 assessing T DM1 63 vidofludimus 63 HuCAL antibody 63 radiation sensitizer 63 ONX 63 MORAb 63 rxRNA 63 Ocrelizumab 63 ospemifene 63 metastatic colorectal 63 CR# vcMMAE 63 mTOR mammalian target 63 trastuzumab DM1 T DM1 63 evaluating T DM1 63 paclitaxel Taxol ® 63 potent antiproliferative 63 dependent kinase inhibitor 63 Epidermal Growth Factor Receptor 63 Panzem R 63 immunotherapeutics 63 ZK EPO 63 Vicinium TM 63 Kahalalide F 63 potent topoisomerase II 63 Curaxin 63 OncoVex 63 HuCAL GOLD R 63 proprietary PEGylation 63 histone deacetylase inhibitor 63 PI3K inhibitor 63 monoclonal antibody 63 lexidronam injection 63 Pancreate 63 therapeutic peptide 63 metastatic castration resistant 63 radiolabeled monoclonal antibody 63 therapeutic monoclonal antibodies 63 angiogenesis inhibition 63 AtuRNAi 63 compound perifosine 63 stable nucleic acid 63 synthetic peptide 63 peptidic compound 63 DEB# 63 FGFR 63 signal transduction inhibitor 63 Sudhir Agrawal D.Phil 63 fusion proteins 63 TLR9 agonists 63 recurrent metastatic ovarian cancer 63 oral ridaforolimus 63 Nexavar sorafenib 63 virus HCV protease inhibitor 63 bevacizumab Avastin R 63 Talabostat 63 UltiMAb 63 erlotinib Tarceva ® 63 5 HT2A serotonin 63 humanized antibodies 63 neratinib 63 CD# antibodies 63 Epratuzumab 63 prostate cancer AIPC 63 Aganocide 63 R sorafenib tablets 63 Alocrest 63 T#I [002] 63 Azedra 63 TKM ApoB 63 XL# XL# XL# XL# 63 MEK inhibitors 63 Dapagliflozin 63 nilotinib Tasigna 63 mitogen activated ERK kinase 63 inhaled formulation 63 generation antisense 63 DepoVax TM 63 Sapacitabine 63 LEX System 63 NS4A 63 EndoTAG TM -1 63 Ridaforolimus 63 gefitinib Iressa 63 small molecule thrombopoietin 63 interferon gamma 1b 63 LNP formulations 63 generation purine nucleoside 63 GV# [001] 63 NS5b 63 tubulin inhibitor 63 SAR# [002] 63 sorafenib tablets 63 thalidomide Thalomid 63 deforolimus 63 PROfusion 63 Reports Preclinical Data 63 RAS MAPK pathway 63 telomerase inhibitor 63 Vaccinex 63 novel emulsion formulation 63 Hsp# Inhibitor 63 PF # [002] 63 PHX# 63 IRX 2 63 auristatin 63 EndoTAG TM 63 Fibroblast Growth Factor Receptor 63 HCV protease inhibitors 63 DiLA2 63 receptor tyrosine kinase inhibitor 63 peptide antigens 63 Anticalins R 63 non nucleoside 63 CCR5 mAb 63 antisense inhibitor 63 receptor inhibiting monoclonal 63 Panitumumab 63 Vandetanib 63 sapacitabine CYC# 63 PSMA antibody 63 pan histone deacetylase 63 ALN VSP 63 apricitabine ATC 63 Nanobody ® 63 NXL# 63 PrevOnco ™ 63 Enkephalin 63 Pazopanib 63 forodesine 63 EGFR HER2 63 Vicriviroc 63 PDL# 63 HGS# 62 OvaRex R 62 SinuNase TM 62 anticancer therapies 62 RGB # 62 imatinib Gleevec ® 62 highly selective endothelin 62 Provectus Pharmaceuticals specializes 62 Novel Oral 62 oral Hsp# inhibitor 62 P#X# antagonist 62 Medarex UltiMAb R 62 POTELLIGENT R Technology 62 MYDICAR ® 62 Voreloxin 62 BRAF inhibitor 62 Completes Patient Enrollment 62 refractory chronic lymphocytic 62 Combination REOLYSIN R 62 CRTH2 62 Luteinizing Hormone Releasing Hormone 62 Guanilib 62 EGFr humanized monoclonal antibody 62 acid phosphatase PAP 62 relapsed refractory multiple myeloma 62 histone deacetylase HDAC inhibitors 62 BRAF kinase 62 JVRS 62 TGR5 62 dSLIM 62 oral JAK#/JAK# inhibitor 62 Novolimus 62 Aurora Kinase 62 gemcitabine cisplatin 62 Degarelix 62 Targeted Chemotherapy 62 Ofatumumab 62 YONDELIS 62 obatoclax 62 LHRH antagonists 62 oral ghrelin agonist 62 Bavituximab 62 Deforolimus 62 Neuvenge 62 PORxin 62 XmAb ® 62 Ixabepilone 62 immunotherapeutic 62 anionic backbone 62 product platforms AZX# 62 atacicept 62 Solazed TM 62 Transdrug ® nanoparticle 62 Phase 1b clinical trials 62 candidate deforolimus 62 non nucleoside HCV 62 kinase inhibitor 62 Amrubicin 62 antisense oligonucleotide 62 novel therapeutic antibodies 62 anti CD# antibodies 62 ErbB3 HER3 62 Bezielle 62 VEGFR2 inhibitor 62 G#DT 62 mda 7 62 R roscovitine CDK cyclin 62 phase IIb clinical 62 bortezomib Velcade 62 castrate resistant prostate cancer 62 anti CD3 antibody 62 Gleevec resistant 62 cellular immunotherapy 62 adenosine A2A 62 introduced NEUGENE 62 enzastaurin 62 selective inhibition 62 cetuximab Erbitux ® 62 Tarmogen 62 SinuNase ™ 62 cyclin dependent kinase inhibitor 62 novel anticancer 62 MET VEGFR2 62 myelofibrosis polycythemia vera 62 busulfan 62 polysaccharide polymer 62 oral Factor Xa 62 Enhanze Technology 62 BiTE antibody 62 Xanafide 62 Abiraterone acetate 62 relapsing multiple sclerosis 62 retinoic acid receptor 62 GlycArt 62 PEGylated Fab fragment 62 mapatumumab 62 5 FU leucovorin 62 Apaziquone 62 maytansinoid 62 lipid nanoparticle 62 Humanized Anti 62 SuperAntibody 62 ATRA IV 62 ABRAXANE ® 62 DCVax ® 62 XmAb ™ 62 generation Hsp# inhibitor 62 gastro intestinal inflammation 62 MEK Inhibitor 62 KRN# 62 Genentech Rituxan 62 fusion inhibitor 62 staphylococcal vaccine 62 Phase 2b Clinical Trial 62 Dalbavancin 62 exon skipping 62 otelixizumab 62 DsiRNA 62 oncolytic vaccine 62 ALN HPN 62 gemcitabine Gemzar ® 62 XmAb TM 62 sphingosine 1 62 XL# XL# XL# 62 FOLFOX6 chemotherapy regimen 62 Xcellerated T Cells 62 HDAC Inhibitor 62 JAK inhibitors 62 LHRH 62 novel VDA molecule 62 CRLX# 62 neuronal nicotinic receptor NNR 62 Telatinib 62 siRNA therapeutics 62 dacetuzumab SGN 62 sodium glucose cotransporter 62 oncolytic viruses 62 transfection reagents 62 Bayer HealthCare Onyx Pharmaceuticals 62 Meets Primary Endpoint 62 HuMax CD# 62 initiated Phase 1b 62 Intravenous Human 62 selectively inhibit 62 metastatic hormone refractory 62 INGN 62 Milatuzumab 62 DXL TM 62 Exherin 62 ABLYNX 62 MKC# MKC# PP 62 small molecule agonists 62 immunotherapeutic vaccine 62 flavopiridol 62 dacetuzumab 62 OvaRex ® MAb 62 Imatinib mesylate 62 Sphingomab 62 ADCC enhanced 62 fluoropyrimidine 62 intratumoral injection 62 leading oral taxane 62 NeoLipid R 62 sunitinib Sutent ® 62 erlotinib Tarceva R 62 immunomodulator 62 anticancer agent 62 Randomized Phase 62 rhMBL 62 Hsp# inhibitor 62 microtubule inhibitor 62 drug monomethyl auristatin 62 Genasense ® oblimersen 62 cytolytic 62 Alnylam RNAi 62 GeneICE 62 Eniluracil 62 MET inhibitor 62 immunotoxins 62 ThermoDox R 62 XL# anticancer compounds 62 MAb 62 proteasome inhibitors 62 anticancer compound 62 cyclin dependent kinase CDK 62 PORxin TM platforms 62 BiTE ® 62 Randomized Phase II 62 Smac mimetics 62 Varespladib 62 HCV polymerase inhibitors 62 IL# PE#QQR 62 RAF kinase 62 tranilast 62 cancer immunotherapy 62 OXi# 62 Etubics 62 Azacitidine 61 Elvitegravir 61 monoclonal antibody therapeutics 61 targeting miR 61 Panzem 61 Atripla combines 61 seliciclib CYC# 61 SCIB1 61 THR beta agonist 61 Uvidem 61 RNA antagonists 61 IMiDs ® 61 hypoxia selective 61 Nanobody R 61 adult mesenchymal stem 61 biased ligand 61 ErbB3 61 HDACi 61 Epothilones 61 biologic therapeutics 61 Tykerb lapatinib 61 cMet 61 OMP #R# 61 soluble tumor necrosis 61 NASDAQ ABII 61 oxidative stress inducer 61 personalized dendritic 61 Calando proprietary 61 TBC# 61 SMaRT ™ 61 TRACON Pharmaceuticals 61 nucleotide analog 61 HIV integrase inhibitor 61 HCV NS5B polymerase 61 CDK inhibitor 61 vaccines oncolytic virus 61 Vaxfectin ® 61 CCR5 antagonist 61 sodium thiosulfate STS 61 Hsp# inhibition 61 Glufosfamide 61 potently inhibit 61 paclitaxel Taxol 61 HuCAL antibodies 61 antisense drug 61 small molecule Hedgehog 61 TG# [003] 61 Small Modular SMIP 61 TRAIL receptor 61 PTH analogue 61 novel immunomodulatory 61 orally dosed 61 panitumumab Vectibix 61 selective modulator 61 interferon lambda 61 cytostatic 61 HTS assay 61 Survivin antagonist 61 drug conjugates ADCs 61 oral Azacitidine 61 triciribine phosphate monohydrate 61 TOCOSOL Paclitaxel 61 OHR/AVR# 61 renin inhibitor 61 Adenosine Therapeutics 61 including eniluracil ADH 61 Squalamine 61 acyclovir Lauriad R 61 Roche SIX RO 61 Symphogen 61 molecularly targeted 61 mAb 61 Tyrima 61 Bruton tyrosine kinase 61 HuMax CD4 61 PI3 K 61 aurora kinase 61 pharmacological chaperone 61 prodrugs 61 beta 1a 61 BRAF inhibitors 61 thymalfasin 61 INSPIRE Trial Phase III 61 Copegus ribavirin 61 HepDirect prodrug 61 docetaxel Taxotere ® 61 Campath alemtuzumab 61 Initiates Clinical 61 adenoviral 61 Vidofludimus 61 drug pipeline TAFA# 61 modulator SERM 61 multicenter Phase II 61 tyrosine kinase inhibitor TKI 61 Ixempra 61 liposome encapsulated 61 INS# [001] 61 antisense drugs 61 CORT # 61 Tumor Necrosis Factor 61 LentiVector technology 61 sulfonylhydrazine class 61 PI3K inhibitors 61 anti CTLA 61 Xencor XmAb 61 ArQule Kinase Inhibitor Platform 61 optimized siRNA 61 Tyrosine Kinase Inhibitor 61 adecatumumab 61 synthetic retinoid 61 stable linker 61 Amira Pharmaceuticals 61 intravesical instillation 61 angiogenesis inhibitor 61 antibody fragment 61 Prodarsan R 61 JAK#/JAK# 61 rusalatide acetate 61 AVEO Pharmaceuticals NASDAQ 61 ELACYT 61 oral picoplatin 61 novel RNAi therapeutics 61 Velcade bortezomib 61 thymidylate synthase TS 61 galiximab 61 molecularly targeted therapy 61 PEGylated 61 pralatrexate injection folate analogue 61 initiate Phase 1b 61 Angiolix 61 trastuzumab Herceptin 61 polyglutamate 61 Sangamo ZFP technology 61 Cethrin R 61 MAXY G# 61 short interfering RNA 61 initiated Phase Ib 61 candidates Azedra TM 61 ApoB SNALP 61 ErbB1 61 Cloretazine R 61 cleavable linker 61 IMiD 61 Receptors GPCRs 61 Monoclonal Antibody 61 lintuzumab 61 SPC# [001] 61 tumor vascular disrupting 61 triphendiol 61 Thiarabine 61 overactive bladder VANTAS R 61 Anticalin 61 mTOR inhibitor 61 oral JAK1 61 BZL# 61 5 HT6 61 HDL Selective Delipidation 61 developing TB4 61 HQK 61 VentiRx Pharmaceuticals 61 Janus kinase 61 Fresenius Biotech 61 selectin antagonist 61 IMiDs ® compound 61 ART# 61 midstage trials 61 novel histone deacetylase 61 RhuDex ® 61 Erbitux cetuximab 61 Interferon beta 61 RNAi therapeutic targeting 61 Transfection Reagent 61 alpha#beta# integrin 61 Santaris 61 Protexia R 61 Trastuzumab 61 inhibit oxidative stress 61 Syncria 61 Vascular Disrupting Agent 61 Listeria vaccine 61 anti EGFR antibody 61 NS#/#A protease 61 Phase Ib study 61 Gefitinib 61 p# inhibitor 61 FVIIa 61 TLR7 agonist 61 Gleevec imatinib mesylate 61 Trofex 61 Temodar ® 61 FORMA Therapeutics 61 Rituxan rituximab 61 lymphoid malignancies 61 bardoxolone 61 Radiation Therapy SIRT 61 axitinib 61 Cetuximab Erbitux 61 mTOR kinase 61 Enzastaurin 61 HDL Mimetic Peptide 61 Aviptadil 61 GLP toxicology studies 61 vinorelbine tartrate 61 Liprotamase 61 regorafenib 61 Initiate Clinical Trial 61 monoclonal antibody IgG1 Mab 61 reformulates existing FDA 61 PXD# 61 doxorubicin Transdrug ® 61 Traficet EN 61 highly selective inhibitor 61 non porcine pancreatic 61 interleukin IL -# 61 Anidulafungin 61 uricase 61 Canvaxin 61 cyclophosphamide methotrexate 61 Thiovir 61 goserelin 61 TransVax TM 61 Preclinical studies suggest 61 TLK# 61 Bicifadine 61 RON Notch 61 registrational trial 61 imatinib Gleevec 61 huN# DM1 61 DU #b 61 Anticancer Agent 61 Vidaza ® 61 Initiates Clinical Trial 60 HCV protease 60 Protexia ® 60 Phase Ib IIa 60 Removab 60 palifosfamide Zymafos TM 60 YONDELIS R 60 prostate cancer antigen prostatic 60 systemic anaplastic large 60 corticosteroid dexamethasone 60 castration resistant prostate cancer 60 RECOTHROM R 60 ALN TTR# 60 HyACT 60 generation antisense inhibitor 60 stated Michelle Berrey 60 GRNOPC1 contains 60 5 HT2C 60 AMPK activators 60 MediVas 60 ADVEXIN p# therapy 60 polymerase inhibitors 60 compound PMX # 60 TOCOSOL 60 mAbs 60 oncolytic virus therapy 60 DAVANAT 60 LEAPS TM 60 mRCC 60 signal transduction inhibitors 60 Valopicitabine 60 telaprevir VX 60 siRNA binds 60 Vascular Endothelial Growth 60 Fc engineered 60 Doxorubicin 60 flu mAb 60 dose escalation clinical 60 imetelstat 60 ixabepilone 60 REGiMMUNE 60 G Protein Coupled 60 NASDAQ ALTH biopharmaceutical 60 Herceptin trastuzumab 60 EHT AGN 60 Presents Preclinical 60 targets Galectin receptors 60 TELINTRA 60 CTLA 4 60 antitumoral 60 cinacalcet HCl 60 custirsen 60 Phase IIb clinical trials 60 humanized therapeutic 60 Nasdaq MITI biopharmaceutical 60 ISF# 60 CYT# novel 60 EZN 60 XOMA 3AB 60 tafamidis 60 Maxy G# 60 ErbB2 positive 60 Imprime PGG 60 Davanat 60 tanespimycin 60 NEUGENE 60 FLT3 60 CoVal TM fusion 60 evaluating picoplatin 60 Affitech AS 60 novel tubulin binding 60 anticancer therapy 60 DCVax 60 TLR agonists 60 using ImmunoGen TAP 60 small molecule chemotherapeutic 60 DermaVir 60 BIIB# 60 Epothilone D 60 investigational hepatitis C 60 recombinant antibodies 60 liposomal doxorubicin 60 AEGR 60 Ii protein 60 eIF 4E 60 Cellerant 60 GPR# agonist 60 sodium Injection 60 zanolimumab 60 Pharmos proprietary 60 Novosom 60 novel antibody therapeutics 60 relapsed ovarian cancer 60 DPX Survivac 60 androgen receptor AR 60 phase IIb trial 60 nicotinic alpha 7 60 Exelixis XL#